Nusinersen – Wikipedia

Nusinersen, marketed as Spinraza, is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. In December 2016, it became the first approved drug used in treating this disorder. Nusinersen cost US$750,000 in the first year and US$375,000 annually after that in the United States as of 2019.

: https://en.wikipedia.org/wiki/Nusinersen